<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36425003</PMID><DateRevised><Year>2022</Year><Month>11</Month><Day>26</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2589-9090</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Journal of translational autoimmunity</Title><ISOAbbreviation>J Transl Autoimmun</ISOAbbreviation></Journal><ArticleTitle>Autoantibodies against SUMO1-DHX35 in long-COVID.</ArticleTitle><Pagination><StartPage>100171</StartPage><MedlinePgn>100171</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">100171</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jtauto.2022.100171</ELocationID><Abstract><AbstractText>Long COVID is a collection of symptoms as a late sequelae of SARS-CoV-2 infection. It often includes mental symptoms such as cognitive symptoms, persisting loss of smell and taste, in addition to exertional dyspnea. A role of various autoantibodies (autoAbs) has been postulated in long-COVID and is being further investigated. With the goal of identifying potentially unknown autoAbs, we screened plasma of patients with long COVID on in-house post-translationally modified protein macroarrays including citrullinated, SUMOylated and acetylated membranes. SUMO1ylated isoform DEAD/H (Asp-Glu-Ala-Asp/His) box helicase 35 (SUMO1-DHX35) was identified as only candidate antigen. In adult patients with long COVID, IgG autoAbs against SUMO1-DHX35 of IgG class were found in seven of 71 (9.8%) plasma samples, of IgM and IgG class in one of 69 (1.4%) samples, not in 200 healthy adult controls, not in 442 healthy children, and 146 children after SARS-CoV-2 infection. All autoAb-positive seven patients were female. AutoAb titers ranged between 200 to up to 400 By point mutagenesis and expression of FLAG-tagged mutants of DHX35 in HEK293&#xa0;cells, and subsequent SUMOylation of purified constructs, lysine 53 was identified as a unique, never yet identified, SUMOylation site. The autoAbs had no reactivity against the non-SUMO1ylated mutant (K53R) of DHX35. To summarize, autoAbs against SUMO1-DHX35 were identified in adult female patients with long-COVID. Further studies are needed to verify the frequency of occurrence. The function of DHX35 has not yet been determined and there is no available information in relation to disease implication. The molecular mechanism causing the SUMOylation, the potential functional consequences of this post-translational modification on DHX35, and a potential pathogenicity of the autoAbs against SUMO1-DHX35 in COVID-19 and other possible contexts remain to be elucidated.</AbstractText><CopyrightInformation>&#xa9; 2022 Published by Elsevier B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Thurner</LastName><ForeName>Lorenz</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Jos&#xe9; Carreras Center for Immuno- and Gene Therapy and Internal Medicine I, Saarland University Medical School, Homburg/Saar, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fadle</LastName><ForeName>Natalie</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Jos&#xe9; Carreras Center for Immuno- and Gene Therapy and Internal Medicine I, Saarland University Medical School, Homburg/Saar, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Regitz</LastName><ForeName>Evi</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Jos&#xe9; Carreras Center for Immuno- and Gene Therapy and Internal Medicine I, Saarland University Medical School, Homburg/Saar, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Preuss</LastName><ForeName>Klaus-Dieter</ForeName><Initials>KD</Initials><AffiliationInfo><Affiliation>Jos&#xe9; Carreras Center for Immuno- and Gene Therapy and Internal Medicine I, Saarland University Medical School, Homburg/Saar, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neumann</LastName><ForeName>Frank</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Jos&#xe9; Carreras Center for Immuno- and Gene Therapy and Internal Medicine I, Saarland University Medical School, Homburg/Saar, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cetin</LastName><ForeName>Onur</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Jos&#xe9; Carreras Center for Immuno- and Gene Therapy and Internal Medicine I, Saarland University Medical School, Homburg/Saar, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schormann</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Jos&#xe9; Carreras Center for Immuno- and Gene Therapy and Internal Medicine I, Saarland University Medical School, Homburg/Saar, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoffmann</LastName><ForeName>Marie-Christin</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Jos&#xe9; Carreras Center for Immuno- and Gene Therapy and Internal Medicine I, Saarland University Medical School, Homburg/Saar, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herr</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine V - Pulmonology, Allergology and Critical Care Medicine, Saarland University, Homburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kheiroddin</LastName><ForeName>Parastoo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>University Children's Hospital Regensburg (KUNO) at the Hospital St. Hedwig of the Order of St. John, University of Regensburg, Regensburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rixecker</LastName><ForeName>Torben Millard</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine V - Pulmonology, Allergology and Critical Care Medicine, Saarland University, Homburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bals</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine V - Pulmonology, Allergology and Critical Care Medicine, Saarland University, Homburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research (HZI), Saarland University Campus, 66123, Saarbr&#xfc;cken, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Muller</LastName><ForeName>Sylviane</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Centre National de la Recherche Scientifique-Universit&#xe9; de Strasbourg, Unit Biotechnology and Cell Signalling, Team Neuroimmunology and Peptide Therapeutics/Strasbourg Drug Discovery and Development Institute, Strasbourg, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thurner</LastName><ForeName>Bernhard</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Klinikum Kempten, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kessel</LastName><ForeName>Christoph</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Pediatric Rheumatology and Immunology, University Children's Hospital Muenster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kabesch</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>University Children's Hospital Regensburg (KUNO) at the Hospital St. Hedwig of the Order of St. John, University of Regensburg, Regensburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bewarder</LastName><ForeName>Moritz</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Jos&#xe9; Carreras Center for Immuno- and Gene Therapy and Internal Medicine I, Saarland University Medical School, Homburg/Saar, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heyne</LastName><ForeName>Kristina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Jos&#xe9; Carreras Center for Immuno- and Gene Therapy and Internal Medicine I, Saarland University Medical School, Homburg/Saar, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lensch</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine V - Pulmonology, Allergology and Critical Care Medicine, Saarland University, Homburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kos</LastName><ForeName>Igor Age</ForeName><Initials>IA</Initials><AffiliationInfo><Affiliation>Jos&#xe9; Carreras Center for Immuno- and Gene Therapy and Internal Medicine I, Saarland University Medical School, Homburg/Saar, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>11</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Transl Autoimmun</MedlineTA><NlmUniqueID>101759413</NlmUniqueID><ISSNLinking>2589-9090</ISSNLinking></MedlineJournalInfo><CoiStatement>LTh received travel grants from Abbvie, Janssen and EUSA-Pharm, and consultancy from Takeda, Astra-Zeneca, Merck, Incyte and EUSA-pharm (less than $10,000 each). CK has received consulting fees from 10.13039/100004336Novartis and 10.13039/501100012112Swedish Orphan Biovitrum (SOBI) (less than $10,000 each) and receives research support from 10.13039/100004336Novartis.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>11</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>11</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>25</Day><Hour>2</Hour><Minute>36</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>26</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>11</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36425003</ArticleId><ArticleId IdType="pmc">PMC9675633</ArticleId><ArticleId IdType="doi">10.1016/j.jtauto.2022.100171</ArticleId><ArticleId IdType="pii">S2589-9090(22)00032-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Arnold D.T., Hamilton F.W., Milne A., et al. Patient outcomes after hospitalisation with COVID-19 and implications for follow-up: results from a prospective UK cohort. Thorax. 2021;76(4):399&#x2013;401. doi: 10.1136/THORAXJNL-2020-216086.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/THORAXJNL-2020-216086</ArticleId><ArticleId IdType="pmc">PMC7716340</ArticleId><ArticleId IdType="pubmed">33273026</ArticleId></ArticleIdList></Reference><Reference><Citation>Carf&#xec; A., Bernabei R., Landi F. Persistent symptoms in patients after acute COVID-19. JAMA. 2020;324(6):603&#x2013;605. doi: 10.1001/JAMA.2020.12603.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/JAMA.2020.12603</ArticleId><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen M.S., Kristiansen M.F., Hanusson K.D., et al. Long COVID in the Faroe Islands: a longitudinal study among nonhospitalized patients. Clin. Infect. Dis. 2021;73(11):E4058&#x2013;E4063. doi: 10.1093/CID/CIAA1792.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/CID/CIAA1792</ArticleId><ArticleId IdType="pmc">PMC7799340</ArticleId><ArticleId IdType="pubmed">33252665</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriano J.B., Murthy S., Marshall J.C., Relan P., Diaz J v. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect. Dis. 2022;22(4):e102&#x2013;e107. doi: 10.1016/S1473-3099(21)00703-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00703-9</ArticleId><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Sivan M., Greenhalgh T., Darbyshire J.L., et al. Protocol: LOng COvid Multidisciplinary consortium Optimising Treatments and servIces acrOss the NHS (LOCOMOTION): protocol for a mixed-methods study in the UK. BMJ Open. 2022;12(5) doi: 10.1136/BMJOPEN-2022-063505.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/BMJOPEN-2022-063505</ArticleId><ArticleId IdType="pmc">PMC9114312</ArticleId><ArticleId IdType="pubmed">35580970</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai F., Tomasoni D., Falcinella C., et al. Female gender is associated with long COVID syndrome: a prospective cohort study. Clin. Microbiol. Infect. 2022;28(4) doi: 10.1016/J.CMI.2021.11.002. 611.e9-611.e16.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.CMI.2021.11.002</ArticleId><ArticleId IdType="pmc">PMC8575536</ArticleId><ArticleId IdType="pubmed">34763058</ArticleId></ArticleIdList></Reference><Reference><Citation>Dotan A., Muller S., Kanduc D., David P., Halpert G., Shoenfeld Y. The SARS-CoV-2 as an instrumental trigger of autoimmunity. Autoimmun. Rev. 2021;20(4) doi: 10.1016/J.AUTREV.2021.102792.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.AUTREV.2021.102792</ArticleId><ArticleId IdType="pmc">PMC7892316</ArticleId><ArticleId IdType="pubmed">33610751</ArticleId></ArticleIdList></Reference><Reference><Citation>Kos I., Balensiefer B., Lesan V., et al. Increased B-cell activity with consumption of activated monocytes in severe COVID-19 patients. Eur. J. Immunol. 2021;51(6):1449&#x2013;1460. doi: 10.1002/EJI.202049163.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/EJI.202049163</ArticleId><ArticleId IdType="pmc">PMC8250224</ArticleId><ArticleId IdType="pubmed">33788264</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo Y., Estes S.K., Ali R.A., et al. Prothrombotic autoAbs in serum from patients hospitalized with COVID-19. Sci. Transl. Med. 2020;12(570):3876. doi: 10.1126/SCITRANSLMED.ABD3876/SUPPL_FILE/ABD3876_SM_DATA_S4.XLSX.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/SCITRANSLMED.ABD3876/SUPPL_FILE/ABD3876_SM_DATA_S4.XLSX</ArticleId><ArticleId IdType="pmc">PMC7724273</ArticleId><ArticleId IdType="pubmed">33139519</ArticleId></ArticleIdList></Reference><Reference><Citation>wei Gao Z., zhong Zhang H., Liu C., Dong K. AutoAbs in COVID-19: frequency and function. Autoimmun. Rev. 2021;20(3) doi: 10.1016/J.AUTREV.2021.102754.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.AUTREV.2021.102754</ArticleId><ArticleId IdType="pmc">PMC7813482</ArticleId><ArticleId IdType="pubmed">33476817</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang S.E., Feng A., Meng W., et al. New-onset IgG autoAbs in hospitalized patients with COVID-19. Nat. Commun. 2021;12(1):1&#x2013;15. doi: 10.1038/s41467-021-25509-3. 2021 12:1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-25509-3</ArticleId><ArticleId IdType="pmc">PMC8440763</ArticleId><ArticleId IdType="pubmed">34521836</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertin D., Brodovitch A., Beziane A., et al. Anticardiolipin IgG autoantibody level is an independent risk factor for COVID-19 severity. Arthritis Rheumatol. 2020;72(11):1953&#x2013;1955. doi: 10.1002/ART.41409/ABSTRACT.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ART.41409/ABSTRACT</ArticleId><ArticleId IdType="pmc">PMC7323091</ArticleId><ArticleId IdType="pubmed">32564467</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastard P., Rosen L.B., Zhang Q., et al. AutoAbs against type I IFNs in patients with life-threatening COVID-19. Science. 2020;(6515):370. doi: 10.1126/SCIENCE.ABD4585.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/SCIENCE.ABD4585</ArticleId><ArticleId IdType="pmc">PMC7857397</ArticleId><ArticleId IdType="pubmed">32972996</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y., Han T., Chen J., et al. Clinical and autoimmune characteristics of severe and critical cases of COVID-19. Clin Transl Sci. 2020;13(6):1077&#x2013;1086. doi: 10.1111/CTS.12805.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/CTS.12805</ArticleId><ArticleId IdType="pmc">PMC7264560</ArticleId><ArticleId IdType="pubmed">32315487</ArticleId></ArticleIdList></Reference><Reference><Citation>Dotan A., Mahroum N., Bogdanos D.P., Shoenfeld Y. COVID-19 as an infectome paradigm of autoimmunity. J. Allergy Clin. Immunol. 2022;149(1):63. doi: 10.1016/J.JACI.2021.11.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.JACI.2021.11.009</ArticleId><ArticleId IdType="pmc">PMC8610602</ArticleId><ArticleId IdType="pubmed">34826507</ArticleId></ArticleIdList></Reference><Reference><Citation>Halpert G., Amital H., Shoenfeld Y. Dysregulation of G protein-coupled receptors of the autonomic nervous system, adrenergic and muscarinic acetylcholine receptors, in patients with autoimmune dysautonomic-related disorders. Brain, Behavior, &amp; Immunity - Health. 2020;4 doi: 10.1016/J.BBIH.2020.100056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.BBIH.2020.100056</ArticleId><ArticleId IdType="pmc">PMC8474541</ArticleId><ArticleId IdType="pubmed">34589842</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu L., Tai Y., Hu S., et al. Bidirectional role of &#x3b2;2-adrenergic receptor in autoimmune diseases. Front. Pharmacol. 2018;9(NOV) doi: 10.3389/FPHAR.2018.01313.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/FPHAR.2018.01313</ArticleId><ArticleId IdType="pmc">PMC6277539</ArticleId><ArticleId IdType="pubmed">30538630</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallukat G., Hohberger B., Wenzel K., et al. Functional autoAbs against G-protein coupled receptors in patients with persistent Long-COVID-19 symptoms. Journal of Translational Autoimmunity. 2021;4 doi: 10.1016/J.JTAUTO.2021.100100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.JTAUTO.2021.100100</ArticleId><ArticleId IdType="pmc">PMC8049853</ArticleId><ArticleId IdType="pubmed">33880442</ArticleId></ArticleIdList></Reference><Reference><Citation>Thurner L, Fadle N, Bewarder M, et al. AutoAbs against Progranulin and IL-1 receptor antagonist due to immunogenic posttranslational isoforms contribute to hyperinflammation in critically ill COVID-19. bioRxiv. Published online October 20, 2021:2021.04.23.441188. doi:10.1101/2021.04.23.441188.</Citation></Reference><Reference><Citation>Pfeifer J., Thurner B., Kessel C., et al. AutoAbs against interleukin-1 receptor antagonist in multisystem inflammatory syndrome in children: a multicentre, retrospective, cohort study. The Lancet Rheumatology. 2022;4(5):e329&#x2013;e337. doi: 10.1016/S2665-9913(22)00064-9/ATTACHMENT/610115D9-EC4A-46D1-AEAD-16C0FF284D4E/MMC1.PDF.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(22)00064-9/ATTACHMENT/610115D9-EC4A-46D1-AEAD-16C0FF284D4E/MMC1.PDF</ArticleId><ArticleId IdType="pmc">PMC8963770</ArticleId><ArticleId IdType="pubmed">35368387</ArticleId></ArticleIdList></Reference><Reference><Citation>Preuss K.D., Pfreundschuh M., Ahlgrimm M., et al. A frequent target of paraproteins in the sera of patients with multiple myeloma and MGUS. Int. J. Cancer. 2009;125(1097&#x2013;0215):656&#x2013;661. (Electronic))</Citation><ArticleIdList><ArticleId IdType="pubmed">19405124</ArticleId></ArticleIdList></Reference><Reference><Citation>Thurner L., M&#xfc;ller A., C&#xe9;rutti M., et al. Wegener's granuloma harbors B lymphocytes with specificities against a proinflammatory transmembrane protein and a tetraspanin. J. Autoimmun. 2011;36(1):87&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">20951001</ArticleId></ArticleIdList></Reference><Reference><Citation>Preuss K.D., Pfreundschuh M., Fadle N., Regitz E., Kubuschok B. Sumoylated HSP90 is a dominantly inherited plasma cell dyscrasias risk factor. J. Clin. Invest. 2015;125(1558&#x2013;8238):316&#x2013;323. (Electronic))</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4382232</ArticleId><ArticleId IdType="pubmed">25485683</ArticleId></ArticleIdList></Reference><Reference><Citation>Merbl Y., Kirschner M.W. Large-scale detection of ubiquitination substrates using cell extracts and protein microarrays. Proc. Natl. Acad. Sci. U. S. A. 2009;106(8):2543&#x2013;2548. doi: 10.1073/pnas.0812892106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0812892106</ArticleId><ArticleId IdType="pmc">PMC2633216</ArticleId><ArticleId IdType="pubmed">19181856</ArticleId></ArticleIdList></Reference><Reference><Citation>Thurner L., Preuss K.D., Fadle N., et al. Progranulin antibodies in autoimmune diseases. J. Autoimmun. 2013;42:29&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">23149338</ArticleId></ArticleIdList></Reference><Reference><Citation>Thurner L., Preuss K.D., Bewarder M., et al. Hyper- N-glycosylated SAMD14 and neurabin-I as driver autoantigens of primary central nervous system lymphoma. Blood. 2018;132(26):2744&#x2013;2753. doi: 10.1182/BLOOD-2018-03-836932.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/BLOOD-2018-03-836932</ArticleId><ArticleId IdType="pubmed">30249786</ArticleId></ArticleIdList></Reference><Reference><Citation>Bewarder M., Kiefer M., Will H., et al. The B-cell receptor autoantigen LRPAP1 can replace variable antibody regions to target mantle cell lymphoma cells. Hemasphere. 2021;5(8):E620. doi: 10.1097/HS9.0000000000000620.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/HS9.0000000000000620</ArticleId><ArticleId IdType="pmc">PMC8274796</ArticleId><ArticleId IdType="pubmed">34263144</ArticleId></ArticleIdList></Reference><Reference><Citation>Bewarder M., Kiefer M., Moelle C., et al. Integration of the B-cell receptor antigen neurabin-I/SAMD14 into an antibody format as new therapeutic approach for the treatment of primary CNS lymphoma. Front. Oncol. 2020;10 doi: 10.3389/FONC.2020.580364.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/FONC.2020.580364</ArticleId><ArticleId IdType="pmc">PMC7689012</ArticleId><ArticleId IdType="pubmed">33282736</ArticleId></ArticleIdList></Reference><Reference><Citation>Klemm P., Assmann G., Preuss K.D., et al. Progranulin autoAbs in systemic sclerosis and autoimmune connective tissue disorders: a preliminary study. Immun Inflamm Dis. 2019;7(4):271&#x2013;275. doi: 10.1002/IID3.270.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/IID3.270</ArticleId><ArticleId IdType="pmc">PMC6842819</ArticleId><ArticleId IdType="pubmed">31502765</ArticleId></ArticleIdList></Reference><Reference><Citation>Owens G.P., Bennett J.L., Lassmann H., et al. Antibodies produced by clonally expanded plasma cells in multiple sclerosis cerebrospinal fluid. Ann. Neurol. 2009;65(6):639&#x2013;649. doi: 10.1002/ANA.21641.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ANA.21641</ArticleId><ArticleId IdType="pmc">PMC2843543</ArticleId><ArticleId IdType="pubmed">19557869</ArticleId></ArticleIdList></Reference><Reference><Citation>Massarenti L., Enevold C., Damgaard D., et al. PADI4 polymorphisms confer risk of anti-CCP-positive rheumatoid arthritis in synergy with HLA-drb1*04 and smoking. Front. Immunol. 2021;12:4065. doi: 10.3389/FIMMU.2021.707690/BIBTEX.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/FIMMU.2021.707690/BIBTEX</ArticleId><ArticleId IdType="pmc">PMC8558474</ArticleId><ArticleId IdType="pubmed">34733271</ArticleId></ArticleIdList></Reference><Reference><Citation>Zamvil S.S., Mitchell D.J., Moore A.C., Kitamura K., Steinman L., Rothbard J.B. T-cell epitope of the autoantigen myelin basic protein that induces encephalomyelitis. Nature. 1986;324(6094):258&#x2013;260. doi: 10.1038/324258A0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/324258A0</ArticleId><ArticleId IdType="pubmed">2431317</ArticleId></ArticleIdList></Reference><Reference><Citation>Schellekens G.A., de Jong B.A.W., van den Hoogen F.H.J., van de Putte L.B.A., van Venrooij W.J. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoAbs. J. Clin. Investig. 1998;101(1):273&#x2013;281. doi: 10.1172/JCI1316.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI1316</ArticleId><ArticleId IdType="pmc">PMC508564</ArticleId><ArticleId IdType="pubmed">9421490</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>